MaxCyte, Inc. (NASDAQ:MXCT) Receives $7.00 Consensus PT from Analysts

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have earned an average recommendation of “Hold” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $7.00.

A number of analysts recently weighed in on MXCT shares. Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th.

MaxCyte Stock Down 2.3%

NASDAQ:MXCT opened at $1.26 on Friday. The company has a market capitalization of $134.40 million, a PE ratio of -2.86 and a beta of 1.22. MaxCyte has a 52-week low of $1.25 and a 52-week high of $5.20. The stock’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.65.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $6.41 million during the quarter, compared to analysts’ expectations of $8.37 million. MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. As a group, sell-side analysts anticipate that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC increased its stake in MaxCyte by 7,935.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock valued at $26,000 after buying an additional 11,665 shares during the period. Prudential Financial Inc. acquired a new stake in shares of MaxCyte in the 2nd quarter worth $26,000. CWM LLC boosted its holdings in shares of MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after acquiring an additional 5,836 shares in the last quarter. May Hill Capital LLC acquired a new position in shares of MaxCyte during the second quarter worth about $27,000. Finally, State of Wyoming purchased a new position in MaxCyte during the second quarter worth about $38,000. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.